vs
Affinity Bancshares, Inc.（AFBI）与Assertio Holdings, Inc.（ASRT）财务数据对比。点击上方公司名可切换其他公司
Assertio Holdings, Inc.的季度营收约是Affinity Bancshares, Inc.的1.6倍（$13.5M vs $8.6M），Affinity Bancshares, Inc.同比增速更快（12.8% vs -57.9%），过去两年Affinity Bancshares, Inc.的营收复合增速更高（8.1% vs -35.4%）
Assertio Therapeutics是一家美国专业制药企业，主要聚焦神经病学、疼痛以及中枢神经系统疾病领域的产品销售与推广。公司前身Depomed成立于1995年，总部位于加利福尼亚州纽瓦克，拥有多款获美国FDA批准的产品，目前在纳斯达克上市。
AFBI vs ASRT — 直观对比
营收规模更大
ASRT
是对方的1.6倍
$8.6M
营收增速更快
AFBI
高出70.7%
-57.9%
两年增速更快
AFBI
近两年复合增速
-35.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $8.6M | $13.5M |
| 净利润 | $2.1M | — |
| 毛利率 | — | — |
| 营业利润率 | 35.9% | -86.7% |
| 净利率 | 24.9% | — |
| 营收同比 | 12.8% | -57.9% |
| 净利润同比 | 58.5% | — |
| 每股收益（稀释后） | $0.34 | $-4.54 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AFBIASRT
| Q4 25 | $8.6M | $13.5M | ||
| Q3 25 | $8.4M | $49.5M | ||
| Q2 25 | $8.3M | $29.2M | ||
| Q1 25 | $7.8M | $26.5M | ||
| Q4 24 | $7.6M | $32.2M | ||
| Q3 24 | $8.0M | $29.2M | ||
| Q2 24 | $8.3M | $31.1M | ||
| Q1 24 | $7.3M | $32.4M |
净利润AFBIASRT
| Q4 25 | $2.1M | — | ||
| Q3 25 | $2.2M | $11.4M | ||
| Q2 25 | $2.2M | $-16.4M | ||
| Q1 25 | $1.8M | $-13.5M | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $1.7M | $-2.9M | ||
| Q2 24 | $1.0M | $-3.7M | ||
| Q1 24 | $1.3M | $-4.5M |
营业利润率AFBIASRT
| Q4 25 | 35.9% | -86.7% | ||
| Q3 25 | 34.9% | 23.2% | ||
| Q2 25 | 34.1% | -27.5% | ||
| Q1 25 | 30.8% | -50.0% | ||
| Q4 24 | 21.1% | -41.9% | ||
| Q3 24 | 28.5% | -10.4% | ||
| Q2 24 | 16.2% | -11.6% | ||
| Q1 24 | 24.0% | -13.4% |
净利率AFBIASRT
| Q4 25 | 24.9% | — | ||
| Q3 25 | 26.5% | 23.1% | ||
| Q2 25 | 25.9% | -56.0% | ||
| Q1 25 | 23.4% | -51.1% | ||
| Q4 24 | 17.7% | — | ||
| Q3 24 | 21.7% | -10.0% | ||
| Q2 24 | 12.5% | -11.8% | ||
| Q1 24 | 18.2% | -13.9% |
每股收益（稀释后）AFBIASRT
| Q4 25 | $0.34 | $-4.54 | ||
| Q3 25 | $0.34 | $0.11 | ||
| Q2 25 | $0.33 | $-0.17 | ||
| Q1 25 | $0.28 | $-0.14 | ||
| Q4 24 | $0.21 | $-3.28 | ||
| Q3 24 | $0.26 | $-0.03 | ||
| Q2 24 | $0.16 | $-0.04 | ||
| Q1 24 | $0.20 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $53.9M | $63.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $127.0M | $94.0M |
| 总资产 | $881.7M | $267.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AFBIASRT
| Q4 25 | $53.9M | $63.4M | ||
| Q3 25 | $84.8M | $93.4M | ||
| Q2 25 | $89.7M | $98.2M | ||
| Q1 25 | $74.7M | $87.3M | ||
| Q4 24 | $41.4M | $100.1M | ||
| Q3 24 | $52.3M | $88.6M | ||
| Q2 24 | $50.4M | $88.4M | ||
| Q1 24 | $61.4M | $80.7M |
总债务AFBIASRT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $38.6M |
股东权益AFBIASRT
| Q4 25 | $127.0M | $94.0M | ||
| Q3 25 | $125.4M | $105.8M | ||
| Q2 25 | $124.1M | $93.3M | ||
| Q1 25 | $122.3M | $108.5M | ||
| Q4 24 | $129.1M | $121.1M | ||
| Q3 24 | $128.4M | $130.5M | ||
| Q2 24 | $125.1M | $132.2M | ||
| Q1 24 | $123.3M | $134.5M |
总资产AFBIASRT
| Q4 25 | $881.7M | $267.0M | ||
| Q3 25 | $925.2M | $319.8M | ||
| Q2 25 | $933.8M | $273.8M | ||
| Q1 25 | $912.5M | $286.4M | ||
| Q4 24 | $866.8M | $284.7M | ||
| Q3 24 | $878.6M | $276.0M | ||
| Q2 24 | $873.6M | $279.4M | ||
| Q1 24 | $869.5M | $282.0M |
负债/权益比AFBIASRT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.29× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.6M | $-30.0M |
| 自由现金流经营现金流 - 资本支出 | $11.2M | — |
| 自由现金流率自由现金流/营收 | 130.9% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | 5.46× | — |
| 过去12个月自由现金流最近4个季度 | $20.3M | — |
8季度趋势，按日历期对齐
经营现金流AFBIASRT
| Q4 25 | $11.6M | $-30.0M | ||
| Q3 25 | $3.7M | $-4.8M | ||
| Q2 25 | $3.8M | $19.1M | ||
| Q1 25 | $1.9M | $-12.5M | ||
| Q4 24 | $6.8M | $11.5M | ||
| Q3 24 | $4.1M | $-35.0K | ||
| Q2 24 | $619.0K | $7.4M | ||
| Q1 24 | $1.2M | $7.5M |
自由现金流AFBIASRT
| Q4 25 | $11.2M | — | ||
| Q3 25 | $3.6M | — | ||
| Q2 25 | $3.7M | — | ||
| Q1 25 | $1.8M | — | ||
| Q4 24 | $6.4M | — | ||
| Q3 24 | $4.0M | — | ||
| Q2 24 | $489.0K | — | ||
| Q1 24 | $1.1M | — |
自由现金流率AFBIASRT
| Q4 25 | 130.9% | — | ||
| Q3 25 | 43.3% | — | ||
| Q2 25 | 44.0% | — | ||
| Q1 25 | 22.7% | — | ||
| Q4 24 | 83.9% | — | ||
| Q3 24 | 49.5% | — | ||
| Q2 24 | 5.9% | — | ||
| Q1 24 | 14.8% | — |
资本支出强度AFBIASRT
| Q4 25 | 4.9% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 5.6% | — | ||
| Q3 24 | 1.7% | 0.0% | ||
| Q2 24 | 1.6% | — | ||
| Q1 24 | 1.8% | — |
现金转化率AFBIASRT
| Q4 25 | 5.46× | — | ||
| Q3 25 | 1.66× | -0.42× | ||
| Q2 25 | 1.75× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 5.05× | — | ||
| Q3 24 | 2.36× | — | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 0.91× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AFBI
暂无分部数据
ASRT
| Products | $12.8M | 95% |
| Other | $719.0K | 5% |
